|
⚲
|
| Keyboard |
| Boxer Capital Management LLC
✚
|
|
|---|---|
| CRD # | 330106 |
| SEC # | 801-130351 |
| CIK # | 0001465837, 0002018299 |
| AUM | 578.2 M (2026-05-11) |
| Employees | 19 (42% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 858-400-3115 |
| Address | 12860 El Camino Real, Ste 300 San Diego, CA 92130 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Generally, BCM is compensated by the receipt of fees based on the value of the Advisory Client’s assets under management (“Management Fees”) and/or the payment of certain performance-based compensation (“Incentive Allocation”). In limited circumstances, BCM receives an agreed upon fixed fee from certain Advisory Client(s). Fund Fees and Compensation As compensation for its advisory services to the Funds, in certain cases BCM receives an asset-based Management Fee, typically equal to a percentage of up to 2% per annum of the net asset value of the Funds’ assets, paid quarterly in advance based on the value of the net assets of the Funds on the last business day of the prior quarter. Typically, BCM would return a pro-rata portion of any fees received in advance if the advisory contract is terminated prior to the end of the billing period. As a general matter, and in accordance with Funds’ Governing Documents, BCM, or its affiliates, may receive performance-based compensation in the form of an Incentive Allocation equal to a percentage of up to 20% of the appreciation in the net asset value of an investor’s capital account in the Fund (as applicable). Management fees and performance fees are deducted from each Fund’s assets and are not billed separately. In certain cases, some Funds may be charged an agreed-upon flat fee, not to exceed an established maximum. BCM, or its affiliates, in its sole discretion, may waive or modify the Incentive Allocation or Management Fees for any Fund investor or any Advisory Client, subject to any applicable regulations and the Funds’ Governing Documents, including investors who are employees and/or affiliates of BCM. Additional information regarding fees and compensation is described in the Funds’ Governing Documents (as applicable). Prospective investors in the Funds should review the Governing Documents in detail before making an investment. Account Fees and Compensation The fee schedule applicable to an Account will be contained in the applicable Investment Management Agreement with BCM. Such compensation is subject to negotiation between BCM and each Account. Such compensation may be deducted from the Account and billed separately as agreed upon between the parties and set forth in their respective investment management agreements. As noted above, BCM may waive or reduce fees, or perform services for no fees, for certain Accounts of employees and/or affiliates of BCM and others in its complete discretion. Expenses Advisory Clients will incur brokerage and other transaction costs, see Section 12 of this brochure which discusses brokerage. Advisory Clients will incur other fees and expenses in connection with BCM’s advisory services. Each Advisory Client will be responsible for certain costs and expenses as detailed in the Governing Documents and/or Investment Management Agreement. Such costs and expenses may include, but are Boxer Capital Management, LLC Form ADV Part 2A not limited to, (i) brokerage fees and commissions and other transaction costs and investment-related expenses incurred in connection with a fund’s investment and trading activities, including, without limitation, expenses related to sourcing, identifying, negotiating, structuring, monitoring, acquiring, holding or selling investments, research and related travel expenses, the costs of any independent accountants or other experts or consultants engaged by BCM in connection with specific investments and expenses associated with unconsummated investments (e.g., “broken-deal” expenses); (ii) clearing and settlement charges; (iii) custody charges and borrowing costs (including with respect to public securities sold short and the payment of withdrawal proceeds); (iv) any interest, fees (including commitment fees), and costs of fund-related borrowings (including borrowings related to positions held on margin); (v) expenses and filing fees related to the ongoing offering of Interests; (vi) routine operational costs such as printing and duplication expenses, legal, accounting, director services, bookkeeping, recordkeeping, licensing fees and related support expenses for order and execution management systems, treasury systems and/or risk management systems, shadow accounting expenses, including licensing fees and expenses of managed services, auditing, consulting and other professional expenses, administration (including the costs and expenses of an administrator, including additional fees for ancillary services), clerical and tax preparation expenses; (vii) information technology expenses associated with all aspects of a fund’s operations and research platforms used on a fund’s behalf (including, without limitation, the costs associated with establishing and maintaining investor reporting systems, and information technology and data security programs and other systems designed to manage and control cyber security risk); (viii) its pro rata portion of any E&O, D&O, or any other form of insurance related to a fund and its management and operations; (ix) exchange, board of trade or other trading or execution facility membership or participation expenses; (x) market data, price quote data and other data, including, but not limited to, research data and alternate data, newswire and data processing expenses, cloud computing and cloud data storage fees and expenses, and connectivity charges; (xi) fees and costs payable in connection with preparing and mailing reports to limited partners of a fund; (xii) compliance related expenses and fees and expenses associated with preparing and submitting regulatory filings required in respect of a fund (e.g., expenses relating to the preparation and filing of SEC Form PF); (xiii) all other ordinary and out-of-pocket expenses of a fund and/or a related master fund; (xiv) all taxes (if any) imposed on a fund and/or a related master fund (or that a fund and/or a related master ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7: Types of Clients As described in Item 4, BCM provides investment advisory services to Funds, Accounts and others it may accept as clients from time to time in its discretion. Investment in Funds sponsored by BCM will generally be limited to investors that meet the eligibility qualifications of both (i) “accredited investors” within the meaning of Regulation D of the Securities Act of 1933, as amended (“Accredited Investors”) and (ii) “qualified purchasers” within the meaning of Section 2(a)(51) of the Investment Company Act of 1940, as amended. Such investors typically will be institutional investors, financial institutions, other investment funds, and high-net-worth individuals, each of whom make representations concerning their financial sophistication and ability to bear the risk of loss respecting their investment in a Fund. Accounts are typically only open to institutional investors, and BCM determines the minimum investment amounts on a case-by-case basis. Typically, such Accounts involve significant minimum investments. The minimum initial investment amount in a Fund is disclosed in the respective Fund’s Governing Documents, which will be provided to Fund investors and prospective investors and is subject to waiver or modification at the discretion of BCM or its affiliates, subject to any applicable regulations. Boxer Capital Management, LLC Form ADV Part 2A |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| BCTG Acquisition Corp | 0.2 | ||
| Kodiak Sciences Inc | 0.1 | ||
| Revolution Medicines Inc | 0.0 | ||
| Kymera Therapeutics Inc | 0.0 | ||
| Celcuity Inc | 0.0 | ||
| Consonance-HFW Acquisition Corp | 0.0 | ||
| Abivax Sa | 0.0 | ||
| Vaxcyte Inc | 0.0 | ||
| Nile Therapeutics Inc | 0.0 | ||
| Protagonist Therapeutics Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Boxer Capital Master Fund LP | [2025-03-31] | 60.2 M | 450.5 M |
| Filed 2025-10-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets $50,000,001 - $100,000,000 | ||||
| HF | Boxer Capital LLC | 2024-10-11 | 127.7 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 0.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 0.6 |
| By Discretionary | ||
| Discretionary | 4 | 0.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 0.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.1 | |
| United States Persons | 0.5 | |
| Total | 4 | 0.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Aaron Davis | Executive Officer | 40 | 4 | |
| Christopher Fuglesang | Executive Officer | 7 | 2 | |
| Boxer Capital GP LLC | Executive Officer | 2 | 2 | |
| Siddarth Subramony | Executive Officer | 1 | 1 | |
| Daniel Effinger | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001465837] | |
| 3 | [0001465837] | |
| 4 | [0001465837] | |
| SC 13D | [0001465837] | |
| SC 13G | [0001465837] | |
| 13F-HR | [0002018299] | |
| 3 | [0002018299] | |
| 4 | [0002018299] | |
| SC 13G | [0002018299] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $2.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900EDWZKUIJFQA680 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-11-06 | Sell | 3,080,000 | $3.14 | 9,671,200 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-10-25 | Sell | 633,000 | $6.87 | 4,348,710 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-10-22 | Sell | 250,000 | $6.78 | 1,695,000 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2024-10-21 | Sell | 625,000 | $7.05 | 4,406,250 |
|
Tyra Biosciences Inc TYRA
Pre-Funded Warrant (right to purchase) · derivative
|
2024-10-18 | Grant | 2,000,000 | ||
|
Tyra Biosciences Inc TYRA
Common Stock
|
2024-10-18 | Disposed to issuer | 2,000,000 | ||
|
iTeos Therapeutics Inc ITOS
Common Stock
|
2024-05-10 | Grant | 1,142,857 | $17.50 | 19,999,998 |
|
Tyra Biosciences Inc TYRA
Common Stock
|
2024-02-06 | Grant | 63,412 | $13.01 | 824,990 |
|
Tyra Biosciences Inc TYRA
Warrant (right to purchase) · derivative
|
2024-02-06 | Grant | 705,280 | $13.01 | 9,175,693 |
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 203,754 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 3,135,966 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 3,201,440 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 30,518 | ||
|
Mirati Therapeutics Inc MRTX
Common Stock
|
2024-01-23 | Disposed to issuer | 287,866 | ||
|
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
|
2024-01-23 | Disposed to issuer | 332,809 | ||
|
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
|
2024-01-23 | Disposed to issuer | 3,578,036 | ||
|
Mirati Therapeutics Inc MRTX
Warrant (right to purchase) · derivative
|
2024-01-23 | Disposed to issuer | 1,413,475 | ||
|
Tango Therapeutics Inc TNGX
Common Stock
|
2023-10-16 | Buy | 500,000 | $6.84 | 3,420,000 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2023-10-13 | Buy | 750,000 | $7.07 | 5,302,500 |
|
Tango Therapeutics Inc TNGX
Common Stock
|
2023-10-09 | Sell | 50,000 | $9.91 | 495,500 |
| showing 20 of 194 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Tensor Edge Capital LLC
✚
|
MA | 584.8 M |
|
Praesidium Investment Management Company LLC
✚
|
NY | 582.9 M |
|
Freshford Capital Management LLC
✚
|
NY | 581.8 M |
|
Cello Capital Management LP
✚
|
NY | 577.2 M |
|
Tabor Asset Management LP
✚
|
NY | 577.2 M |
|
Birnam Oak Advisors LP
✚
|
NY | 577.0 M |
|
Muddy Waters Capital LLC
✚
|
TX | 576.3 M |
|
Western Standard LLC
✚
|
CA | 574.9 M |
|
Untitled Investments LP
✚
|
NY | 574.0 M |
|
Prevatt Capital Ltd
✚
|
571.5 M |